Dailypharm Live Search Close

Multiple myeloma drug Elrexfio receives conditional approval

By Lee, Hye-Kyung | translator Kang, Shin-Kook

24.06.17 05:21:37

°¡³ª´Ù¶ó 0
CPAC ¡°company should submit therapeutic confirmatory clinical trial test results¡±



The orphan drug ¡®Elrexfio (elranatamab)' that is being imported by Pfizer Korea, has been approved subject to the submission of therapeutic confirmatory clinical trial data.

Elrexfio is an orphan drug indicated as monotherapy to treat adult patients with relapsed or refractory multiple myeloma who have received three or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody

Being a subcutaneously delivered B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody (BsAb) immunotherapy, it owns the advantage of being able to be administered immediately compared to CAR-T cell therapy.

After rece

Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)